Ras proteins are small molecular switches inside your cells that relay growth signals from the cell surface to the nucleus. When a Ras gene picks up certain mutations, the protein gets stuck in its “on” position, continuously telling the cell to grow and divide even when no external signal is present. This permanent activation drives roughly a quarter of all human cancers, making Ras one of the most commonly mutated cancer-causing genes ever identified. The story of how a tiny protein barely 21 kilodaltons in size can hijack cell behavior involves a surprisingly elegant switching mechanism, and understanding it has reshaped cancer drug development over the past decade.
How the Ras Switch Works in Healthy Cells
Ras acts like a binary switch that flips between two shapes. When bound to a molecule called GTP, Ras is “on” and can grab onto downstream partner proteins to pass along signals for growth, survival, and differentiation. When that GTP gets broken down into GDP, Ras snaps into a different shape and lets go of those partners, turning the signal off. The physical shape change that accompanies this GTP-to-GDP transition is what makes the whole system work as a true on-off switch.
1PubMed Central. The structural basis for the transition from Ras-GTP to Ras-GDPCells don’t leave this switching to chance. Two families of helper proteins tightly control it. Exchange factors (GEFs) pry GDP off of Ras, allowing GTP to rush in and flip the switch on. Because GTP floats around inside cells at concentrations roughly ten to twenty times higher than GDP, the swap happens almost automatically once GDP is removed. On the other side, accelerator proteins called GAPs dramatically speed up the rate at which Ras breaks down GTP back to GDP, increasing the natural rate by several orders of magnitude. Together, GEFs and GAPs set the pace of signaling, making sure Ras flicks on briefly when a growth signal arrives and then promptly turns off again.
2Biochemical Journal. Dynamic regulation of RAS and RAS signalingThe process typically starts when a growth factor outside the cell binds to a receptor on the cell surface. That receptor activates a GEF called SOS, which flips Ras on. Ras-GTP then activates downstream pathways, and GAPs quickly reset Ras to its off state. The whole burst of Ras activity is meant to be brief and tightly controlled.
3PubMed Central. Mechanisms through which Sos-1 coordinates the activation of Ras and RacWhat Goes Wrong When Ras Mutates
The mutations that turn Ras into a cancer driver cluster at a handful of specific spots in the protein, mainly at positions 12, 13, and 61. These positions sit right in or near the region where GTP is held and broken down. When one of these amino acids changes, two things happen: the protein can no longer efficiently break down GTP on its own, and GAPs can no longer help it. The result is a Ras protein that stays loaded with GTP and locked in its active shape, pumping out growth signals without pause.
4PubMed Central. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4BResearch into exactly how these mutations distort the protein’s structure has shown that different substitutions at the same position produce different degrees of disruption. Mutations at position 12, such as G12C or G12V, push a critical loop region away from its normal neighbors, breaking a salt bridge that normally holds the protein in the right configuration for GTP breakdown. The Q61H mutation at position 61 disrupts things differently, altering the organization of a catalytic residue that GAPs rely on to do their job. These structural details matter because they help explain why some mutations are more aggressive than others and why they respond differently to drugs.
5PubMed Central. Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-RasA single mutant Ras allele is rarely enough to produce a full-blown cancer on its own. Cancer typically requires several mutations accumulating over time. But a stuck-on Ras protein provides a powerful head start by creating a cell that divides more than it should, resists signals telling it to stop or die, and gradually accumulates the additional genetic damage needed for a tumor to form.
Three Flavors of Ras and the Cancers They Favor
Humans carry three Ras genes, called KRAS, HRAS, and NRAS. They encode proteins that look very similar and use the same switching mechanism, but accumulating evidence shows they are not interchangeable. Each isoform follows different processing routes inside the cell, localizes to different membrane compartments, and connects with different networks of downstream genes depending on the tissue.
6PubMed Central. Functional specificity of ras isoforms: so similar but so differentThis functional specificity lines up with a striking pattern in cancer: certain Ras isoforms are preferentially mutated in certain tumor types. KRAS mutations dominate in pancreatic cancer, colorectal cancer, and lung adenocarcinoma. NRAS mutations show up most often in melanoma and certain blood cancers. HRAS mutations are rarer overall but crop up in bladder cancer and some head and neck tumors. These tissue-specific preferences suggest that each isoform plays distinct developmental roles in different cell lineages, so mutating one has different consequences depending on where it happens.
7PubMed. Isoform-specific ras functions in development and cancerKRAS is by far the most commonly mutated of the three in human cancers, which is why the drug development effort has focused heavily on it. When you hear about “Ras-driven cancers” in clinical contexts, the conversation is usually about KRAS.
The Downstream Cascade
When Ras is stuck on, it doesn’t cause cancer through a single effect. It simultaneously activates several signaling highways inside the cell, each of which contributes a different piece of the cancer puzzle.
The best-studied route is the MAPK pathway, sometimes called the Ras-Raf-MEK-ERK cascade. Active Ras grabs a protein called Raf, which activates MEK, which activates ERK, which travels into the nucleus and flips on genes involved in cell division. This chain of events is central to how many cancers grow, and targeting various links in the chain has been a major strategy in cancer therapy.
8Genes & Diseases. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsA second major route runs through PI3K and a survival protein called Akt. While the MAPK pathway mostly drives proliferation, the PI3K-Akt pathway keeps cells alive by suppressing programmed cell death. Research on keratinocytes has shown that H-Ras signaling through PI3K and Akt plays a key role in cell survival even under conditions that would normally trigger cells to self-destruct.
9PubMed. Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytesWith both pathways running simultaneously, a cell with mutant Ras is dividing faster than normal and refusing to die when it should. That combination is a recipe for tumor growth.
How Mutant Ras Reshapes the Tumor’s Neighborhood
The damage from oncogenic Ras signaling extends well beyond the cancer cell itself. Mutant KRAS reshapes the tissue surrounding the tumor in ways that help the cancer grow and hide from the immune system. Evidence shows that oncogenic Ras signaling alters fibroblast activation, ramps up production of the structural scaffold around tumors, and changes which inflammatory molecules the tumor secretes. These changes can restrict the ability of immune cells to mount an effective attack and may contribute to treatment resistance.
10PubMed Central. RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapyThe immunosuppressive effects are remarkably coordinated. KRAS-mutant tumors can downregulate the machinery that displays abnormal proteins on the cell surface for immune detection, expand populations of immune-suppressing cells, reprogram immune cells called macrophages from their tumor-fighting mode into a tumor-promoting mode, and increase expression of PD-L1, a molecular “don’t eat me” signal that exhausts attacking immune cells. The net effect is a tumor microenvironment that actively excludes or disarms the immune response.
11PubMed Central. KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapiesThis immune evasion partly explains why KRAS-mutant cancers like pancreatic adenocarcinoma have been so resistant to immunotherapy. Even when the immune system has T cells capable of recognizing the tumor, the local environment built by Ras signaling can prevent those cells from doing their job.
Metabolic Tricks of Ras-Driven Tumors
Mutant Ras also gives cancer cells a metabolic edge. Tumors often outgrow their blood supply and end up starving for nutrients. Ras-driven cancer cells solve this problem by ramping up a process called macropinocytosis, essentially drinking in large gulps of surrounding fluid along with any proteins floating in it. Those engulfed proteins get broken down inside the cell and recycled into amino acids that fuel growth. This scavenging pathway allows Ras-mutant tumors to thrive even in nutrient-poor conditions that would stall other cells.
12PubMed Central. Macropinocytosis: A Metabolic Adaptation to Nutrient Stress in CancerWhy Ras Was Called “Undruggable” for Decades
Despite being one of the most important targets in cancer biology, Ras earned a notorious reputation as “undruggable.” The protein’s surface is smooth and relatively featureless, lacking the deep pockets that drugs typically nestle into. It also clings to GTP with extremely high affinity, making it hard to design a small molecule that could compete for the binding site the way many drugs work against other targets.
13PubMed Central. Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic StrategiesEarly attempts to block Ras indirectly by preventing it from reaching the cell membrane, where it needs to sit in order to signal, largely failed in clinical trials. Drugs called farnesyltransferase inhibitors were designed to block one of the chemical modifications Ras needs to anchor itself to membranes. Ras undergoes an elaborate series of modifications at its tail end, including farnesylation, cleavage, methylation, and sometimes palmitoylation, all of which guide it to the right membrane location.
14PubMed Central. Regulating the regulator: post-translational modification of RASBut KRAS and NRAS turned out to have backup processing routes, so blocking farnesylation alone wasn’t enough to keep them off the membrane.
The breakthrough came with the discovery that the G12C mutation, where a glycine at position 12 is replaced by a cysteine, creates a tiny new pocket on the protein’s surface. That cysteine’s reactive chemistry gave drug designers something to grab onto. Two drugs, sotorasib and adagrasib, were developed to slip into this pocket and lock KRAS G12C in its inactive GDP-bound form. Their approval for lung cancer marked the first time any drug had directly targeted a mutant Ras protein in patients, ending four decades of “undruggable” status.
The Resistance Problem
The excitement around KRAS G12C inhibitors was tempered quickly by the reality of drug resistance. In a study of patients treated with adagrasib, resistance mechanisms were detected in about 45% of those whose tumors were sequenced after progression. The resistance landscape was strikingly diverse: some tumors acquired new KRAS mutations at entirely different positions, some amplified the mutant KRAS gene to overwhelm the drug, and others bypassed KRAS entirely by activating other oncogenes like MET, NRAS, BRAF, or RET. In two patients, the tumor even changed its tissue type, transforming from lung adenocarcinoma into squamous-cell carcinoma.
15PubMed Central. Acquired Resistance to KRAS(G12C) Inhibition in CancerA larger genomic study of 143 patients treated with KRAS G12C inhibitors found a similar picture: about 46% developed at least one new alteration in the Ras-MAPK pathway after treatment, and roughly a quarter had multiple concurrent resistance changes. The most common categories included amplification of the KRAS gene itself, new activating KRAS mutations, mutations that altered the drug-binding pocket, and activation of downstream pathway members like BRAF and MAP2K1.
16Annals of Oncology. Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitorsLab studies have drilled further into the mechanisms. One study found that long-term treatment with sotorasib led to upregulation of a protein called AURKA, which formed a feedback loop with another protein that reactivated the PI3K-Akt survival pathway, essentially routing around the KRAS blockade. Combining an AURKA inhibitor with sotorasib overcame this resistance in cell and animal models.
17PubMed Central. AURKA/PHB2 signaling drives acquired resistance to KRAS (G12C) inhibitors in KRAS (G12C)-mutant NSCLCThe theme that emerges from all of this is that tumors have many escape routes. Blocking one node in a signaling network as heavily wired as the Ras pathway creates strong selective pressure for cells that find a workaround.
Next-Generation Drugs and Combination Strategies
The limitations of first-generation KRAS G12C inhibitors have driven a wave of new approaches. One of the most promising is the concept of “pan-Ras” inhibitors, drugs designed to block multiple Ras mutant forms rather than just G12C. These work as molecular glues: they recruit a cellular chaperone protein to form a three-way complex with mutant Ras, physically blocking it from engaging downstream partners. Preclinical candidates such as HZ-V055 have shown improved selectivity for common KRAS mutations like G12C, G12D, and G12V over normal Ras, which could widen the therapeutic window and reduce side effects from shutting down Ras signaling in healthy tissues.
18Cancer Research. Abstract LB345: HZ-V055, an oral, highly potent pan-Ras molecular glue inhibitor demonstrated robust potency in RasMut cancer modelsOther pan-Ras candidates like RCZY-690 target both mutant and normal Ras in their active GTP-bound state, aiming to block oncogenic signaling even when tumors switch Ras isoforms as a resistance mechanism.
19Cancer Research. Abstract 5778: RCZY-690: A tri-complex molecular glue pan-RAS (ON) inhibitor exhibiting best-in-class potential for RAS-addicted solid tumorsCombination therapy is the other major frontier. Blocking the GEF protein SOS1, which activates Ras upstream, is being tested alongside KRAS inhibitors and MEK inhibitors. The idea is that SOS1 inhibitors act as “multiplier” drugs, making the downstream blockade more effective while also cutting off a potential escape route.
20PubMed Central. Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapyAnother angle targets the compensatory signaling that kicks in when one pathway is blocked. Inhibiting a protein called SHP2 upstream of Ras suppresses MAPK signaling but triggers a compensatory surge through PI3K-Akt. Researchers have found that combining SHP2 inhibitors with ERK inhibitors produces synergistic effects in pancreatic cancer models, shutting down both the main pathway and its backup simultaneously.
21PubMed. SHP2 Inhibition Reveals Compensatory PI3K-AKT Activation in KRAS-Driven Pancreatic Cancer: Discovery of SDUY104 and Rational Approaches for Combination TherapyRASopathies and What They Reveal
Not every Ras pathway mutation causes cancer. A group of developmental disorders called RASopathies arise from inherited mutations in Ras pathway genes that are present in every cell from birth. These include Noonan syndrome, Costello syndrome, cardio-facio-cutaneous syndrome, neurofibromatosis type 1, and Legius syndrome. They share overlapping features: growth problems, distinctive facial features, heart defects, skin abnormalities, and variable degrees of cognitive difficulty.
22PubMed Central. The RASopathiesThe mutations behind RASopathies activate Ras-MAPK signaling, but typically more mildly than the mutations found in cancer. The difference between a developmental disorder and a tumor often comes down to the strength and context of the signal: a moderate increase in Ras activity during embryonic development can alter how tissues form without necessarily driving uncontrolled growth. Still, children with RASopathies do carry a higher risk of certain cancers, particularly abnormal proliferation of blood-forming cells in infancy.
23Haematologica. RAS diseases in children – Section: Genetic syndromes of the RAS/mitogen-activated kinase pathwayStudying RASopathies has proved valuable for cancer researchers because these disorders provide a natural experiment in what happens when the Ras pathway is dialed up to different levels in different tissues. The clinical overlap between RASopathies and certain pediatric cancers has reinforced the idea that Ras pathway activity operates on a spectrum, where low-level activation causes developmental defects and high-level activation, combined with additional mutations, pushes cells toward malignancy.
24PubMed Central. RASopathies: From germline mutations to somatic and multigenic diseasesHow Ras Was First Discovered
The name “Ras” comes from rat sarcoma. In the 1960s, researchers Jenny Harvey and Werner Kirsten found that certain mouse leukemia viruses could, at high doses, produce solid tumors called sarcomas in rats. The transforming genes carried by those viruses were eventually isolated and named H-ras and K-ras after their discoverers. From 1979 onward, researchers including Robert Weinberg began fishing similar oncogenes out of human tumor DNA using a technique called transfection, confirming that human cancers carried their own activated versions of the same genes. A third family member, NRAS, was discovered shortly after.
25PubMed Central. A perspective on the early days of RAS researchMuch of the early understanding of how Ras works in living organisms came not from human cells but from a tiny roundworm, C. elegans. Genetic studies in the worm clarified which proteins worked upstream and downstream of Ras and revealed new regulators that no one had anticipated. Because the worm’s development follows a rigid, cell-by-cell blueprint, researchers could trace Ras signaling’s effects on the fate of individual cells, mapping the pathway with a precision that was impossible in mammalian systems at the time.
26PubMed Central. Genetics of RAS signaling in C. elegansThat lineage from rat sarcoma viruses through worm genetics to the first approved KRAS inhibitor spans about sixty years of research. It is one of the longer arcs in molecular oncology, and the fact that Ras resisted direct therapeutic targeting for most of that time makes the recent wave of drugs feel earned in a way that few other advances do.